COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT00056472
Previous Study | Return to List | Next Study

Study of Pharmacotherapy of Psychotic Depression (STOP-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00056472
Recruitment Status : Completed
First Posted : March 17, 2003
Results First Posted : August 2, 2013
Last Update Posted : August 2, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder With Psychotic Features Drug: Olanzapine Drug: Sertraline Other: placebo Phase 3

Detailed Description:

Approximately 25% of people who are admitted to hospitals for depression suffer from psychotic depression. People with psychotic depression experience hallucinations,and, more commonly delusions, in addition to major depression. Psychotic experiences may be either congruent with the theme of depression or incongruent, without an apparent relationship to feeling depressed. This study will determine the effectiveness of combining a selective serotonin reuptake inhibitor (SSRI) with antipsychotic medication in the treatment of psychotic depression accompanied by at least one identifiable delusion. The study will also evaluate the difference in treatment response of young adults versus geriatric patients.

This double-blind study will last a total of 12 weeks. Participants will be randomly assigned to receive either olanzapine, an atypical antipsychotic drug, combined with sertraline, an SSRI, or olanzapine alone. Following baseline assessments, study visits will occur weekly until Week 6, and then bi-weekly until Week 12. Participants who do not respond to either treatment may leave the study at any time. Participants who achieve either partial or full response may participate in an additional 20-week study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 259 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression
Study Start Date : January 2003
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: olanzapine/sertraline combination
sertraline plus olanzapine
Drug: Olanzapine
Other Name: Zyprexa

Drug: Sertraline
Other Name: Zoloft

Placebo Comparator: olanzapine plus placebo
olanzapine (5 - 20mg/day) plus placebo
Drug: Olanzapine
Other Name: Zyprexa

Other: placebo
tablet that ressembles sertraline but contains no medication

Primary Outcome Measures :
  1. Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial [ Time Frame: Weeks 1 to 12 ]

    Remission was defined as scores on Ham-D of less than 10 at two consecutive assessments and the absence of delusions (measured as SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval.

    Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression. Scores on SADS range from 1 to 7 with higher scores indicating the delusions(s) more adversely effect the subject's behavior.

Secondary Outcome Measures :
  1. Scores on CGI-S Compared to Baseline Over the Course of the Trial [ Time Frame: Weeks 1 to 12 ]
    A measure of overall symptom severity, the Clinical Global Impressions, Severity of Illness Scale (CGI-S). It is a seven point scale with a one indicating not at all ill, and seven indicating the most extremely ill. This rating was done each week after baseline by the PI at each site after visiting with the patient.

Other Outcome Measures:
  1. Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week. [ Time Frame: Weeks 1 to 12 ]
    The Ham-D measures depression severity. Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Major depressive disorder, single or recurrent, with psychotic features

Exclusion Criteria:

  • History of substance abuse or dependence within the 3 months prior to enrollment
  • Acute or unstable medical illness
  • Diagnosis of schizophrenia or other psychotic disorders
  • Pregnant
  • Intolerance to SSRIs or olanzapine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00056472

Layout table for location information
United States, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01605
United States, New York
Cornell University
New York, New York, United States, 10021
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
Weill Medical College of Cornell University
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Barnett Meyers, MD Cornell University
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University Identifier: NCT00056472    
Other Study ID Numbers: U01MH062624 ( U.S. NIH Grant/Contract )
U01MH062624 ( U.S. NIH Grant/Contract )
U01MH062565 ( U.S. NIH Grant/Contract )
U01MH062518 ( U.S. NIH Grant/Contract )
U01MH062446 ( U.S. NIH Grant/Contract )
First Posted: March 17, 2003    Key Record Dates
Results First Posted: August 2, 2013
Last Update Posted: August 2, 2013
Last Verified: June 2013
Keywords provided by Weill Medical College of Cornell University:
Major depressive disorder with psychotic features
Delusional Depression
Randomized Trial
Combination Treatment
Atypical Antipsychotic
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mental Disorders
Psychotic Disorders
Behavioral Symptoms
Mood Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents